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OBJECTIVES: To determine the association between cog-
nition and levels of cystatin C in persons with chronic kid-
ney disease (CKD).
DESIGN: Prospective observational study.
SETTING: Chronic Renal Insufficiency Cohort Cognitive
Study.
PARTICIPANTS: Individuals with a baseline cognitive
assessment completed at the same visit as serum cystatin C
measurement (N = 821; mean age 64.9, 50.6% male,
48.6% white).
MEASUREMENTS: Levels of serum cystatin C were cate-
gorized into tertiles; cognitive function was assessed using
six neuropsychological tests. Scores on these tests were
compared across tertiles of cystatin C using linear regres-
sion and logistic regression to examine the association
between cystatin C level and cognitive performance (1
standard deviation difference from the mean).
RESULTS: After multivariable adjustment for age, race,
education, and medical comorbidities in linear models,
higher levels of cystatin C were associated with worse cogni-
tion on the modified Mini-Mental State Examination,
Buschke Delayed Recall, Trail-Making Test Part (Trails) A
and Part B, and Boston Naming (P < .05 for all). This asso-
ciation remained statistically significant for Buschke
Delayed Recall (P = .01) and Trails A (P = .03) after addi-
tional adjustment for estimated glomerular filtration rate
(eGFR). The highest tertile of cystatin C was associated with
greater likelihood of poor performance on Trails A (odds
ratio (OR) = 2.17, 95% confidence interval (CI) = 1.16–
4.06), Trails B (OR = 1.89, 95% CI = 1.09–3.27), and Bos-
ton Naming (OR = 1.85, 95% CI = 1.07–3.19) than the
lowest tertile after multivariate adjustment in logistic models.
CONCLUSION: In individuals with CKD, higher serum
cystatin C levels were associated with worse cognition and
greater likelihood of poor cognitive performance on attention,
executive function, and naming. Cystatin C is a marker of
cognitive impairment and may be associated with cognition
independent of eGFR. J Am Geriatr Soc 62:1623–1629, 2014.
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Cystatin C, a protease inhibitor, has been studied as ameasure of kidney function and as a biomarker of
cognitive impairment.1–3 In a number of community-based
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cohort studies, high cystatin C levels were associated with
greater risk of cognitive impairment,4,5 whereas other
observational studies have reported an association between
low cystatin C levels (in serum and cerebrospinal fluid)
and greater risk of dementia.6,7 Cystatin C has also been
linked to risk of cognitive impairment in genetic and neu-
ropathological studies. A common polymorphism of the
cystatin C gene is associated with greater risk of Alzhei-
mer’s disease (AD),8–10 and cystatin C colocalizes with b-
amyloid in the brain, especially in areas involved in AD
pathology.11,12
Age, sex, and muscle mass affect cystatin C, as a mea-
sure of kidney function, much less than serum creati-
nine.13,14 Studies also suggest that cystatin C is a
prognostic indicator of adverse health outcomes, although
it is unclear whether these associations are independent of
cystatin C’s role as a marker of glomerular filtration
rate.15 In older adults, higher levels of cystatin C are asso-
ciated with greater risk of mortality, cardiovascular events,
and poor physical function,4,16–18 and in individuals with
chronic kidney disease (CKD), cystatin C may predict kid-
ney decline and progression to end-stage kidney disease
and identify those at risk of heart failure and mortal-
ity.14,19 Although individuals with CKD are also at high
risk for cognitive decline and dementia,20–22 the potential
of cystatin C as a marker of poor cognitive performance in
this population has not been investigated.
The Chronic Renal Insufficiency Cohort (CRIC) Study,
a prospective observational study, was designed to deter-
mine the association between cystatin C levels and cogni-
tive function according to six cognitive tests in older
adults with CKD and to evaluate whether this association
was independent of estimated glomerular filtration rate
(eGFR). It was hypothesized that higher serum cystatin C
level would be associated with worse cognitive perfor-
mance and that this association would remain significant
even after adjusting for eGFR.
METHODS
Setting
The CRIC Cognitive (CRIC COG) Study is an ancillary
study of the CRIC Study.
Parent Study
Participants enrolled in the main CRIC Study from seven
clinical centers across the United States (July 1, 2003 to
December 31, 2006) were aged 21 to 74 and had an eGFR
of 20 to 70 mL/min per 1.73 m2 if aged 21 to 44, 20 to
60 mL/min per 1.73 m2 if aged 45 to 64, and 20 to
50 mL/min per 1.73 m2 if aged 65 to 74. Participants were
considered ineligible if they were institutionalized, did not
provide informed consent, had previously undergone dialy-
sis for longer than 1 month, were diagnosed with polycys-
tic kidney disease, had received a prior organ or bone
marrow transplant, had taken immunosuppressive drugs
for kidney in the past 6 months, or were currently partici-
pating in a clinical trial or an ongoing cohort study at
some of the centers (the African American Study of Kidney
Disease and Hypertension). Other exclusion criteria were
New York Heart Association Class III or IV heart failure,
cirrhosis, human immunodeficiency infection or acquired
immunodeficiency syndrome, chemotherapy for cancer
within 2 years, multiple myeloma, or renal cell carcinoma.
Additional details of the parent study have been previously
published.23
CRIC COG Study
CRIC COG studied cognitive function in elderly adults
(eligibility criteria: aged ≥55 and enrolled in the main
CRIC Study) with CKD.24 Participants were recruited
from four of the seven clinical CRIC centers located in
Philadelphia, Pennsylvania; Cleveland, Ohio; Oakland,
California; and Chicago, Illinois. Of the 825 CRIC COG
participants (83.9% of those invited to participate, all
English speaking), 821 completed a cognitive assessment
and had cystatin C measurement during the same in-clinic
visit of the CRIC parent study. The institutional review
boards at each of the participating sites and at the Univer-
sity of California at San Francisco approved the study. All
participants gave written informed consent.
Predictor Variable
Blood samples were collected during the main CRIC clinic
visit. Samples were stored at 80°C, and cystatin C was
measured at the CRIC central laboratory using a nephe-
lometer (BN II ProSpec, Siemens Healthcare Diagnostics,
Deerfield, IL) that used a particle-enhanced immunone-
pholometric assay (N Latex Cystatin C, Dade Behring,
Inc., Deerfield, IL), with a coefficient of variation of
4.9%.25 To correct for drift over time when using different
calibrator and reagent lots, an internal standardization for
CRIC cystatin C was implemented.26 Cystatin C values for
the 821 participants (range 0.55–6.59 mg/L) were catego-
rized into tertiles of low (≤1.230 mg/L), middle (1.231–
1.710 mg/L), and high levels (>1.711 mg/L).
Cognitive Function Measures
Baseline cognitive testing consisted of six interviewer-
administered tests in English: the Modified Mini-Mental
State Examination (3MS, global cognitive function), the
Trail-Making Test Part A (Trails A, attention) and B
(executive function), Category Fluency (verbal fluency), the
Buschke Selective Reminding Test—Delayed Recall
(delayed memory), and the Boston Naming Test (naming).
The 3MS is a general cognitive battery assessing orienta-
tion, concentration, language, praxis, and immediate and
delayed memory. Scores on the 3MS range from 0 to 100,
with higher scores indicating better function.27 Visuospa-
tial scanning, motor speed, executive function, and atten-
tion are all measured using Trails A and B, but Trails A is
largely a test of attention in which participants draw a line
between randomly placed numbered circles in sequence
and Trails B is primarily a test of executive function in
which participants draw a line between alternating pat-
terns of circled letters and numbers in sequence. Scores
range from 0 to 300, with lower scores (seconds) indicat-
ing better function, because they are based on the time to
complete a particular task.28 Category Fluency evaluates
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verbal production, semantic memory, and language. It
measures the number of animals named in a 1-minute per-
iod. Higher scores indicate better function.29 The Buschke
Selective Reminding Test measures verbal memory with
delayed components. Participants are read a list of 12
words and asked to recall as many as possible after one
trial (immediate recall) and after a 20- to 30-minute delay
(delayed recall) higher scores indicate better perfor-
mance.30 The Boston Naming Test assesses language func-
tion by asking participants to name 15 objects presented
in pictures; higher scores indicate higher function.29
For each cognitive test, test-specific clinically signifi-
cant poor cognitive performance was defined as a score 1
standard deviation (SD) or more below the mean for the
3MS, Verbal Fluency, Buschke Delayed Recall, and the
Boston Naming tests. For Trails A and B, lower scores
indicate better function, and poor cognitive performance
on each test was defined as a score 1 SD or more above
the mean.
Covariates
All covariates were measured at the same visit for the par-
ent study, as was the baseline cognitive assessment. Demo-
graphic variables included age, sex, race, Hispanic
ethnicity, and education. Comorbid conditions were identi-
fied through participant self-report; laboratory test values;
and use of medications for diabetes mellitus, stroke, hyper-
tension, and coronary heart disease. Serum creatinine was
calibrated to isotope dilution mass spectrometry and used
to estimate GFR using the Modification of Diet in Renal
Disease estimating equation.31
Statistical Analyses
To assess whether there was a linear trend in participant
characteristics across cystatin C tertiles, analyses of vari-
ance (ANOVAs) were used for continuous variables, along
with an orthogonal polynomial contrast for test of linear
trend, and the Cochran-Armitage trend test was used for
categorical variables. The relationship between eGFR and
cystatin C was examined using a Pearson correlation. An
ANOVA model along with an orthogonal polynomial con-
trast was also used to test for a linear trend in the associa-
tion between cystatin C tertile and cognitive function
score. Models were also adjusted for age, race, education,
and medical comorbidities that were significantly associ-
ated with cystatin C in bivariate analyses (P < .10).
Finally, models were also adjusted for eGFR to investigate
whether the association between cystatin C and cognition
was independent of eGFR level. An interaction between
cystatin C level and age group (<65, 65–74, ≥75) was also
tested for.
To examine the association between cystatin C level
and clinically significant poor cognitive performance, odds
ratios (ORs) and 95% confidence intervals (CIs) were mea-
sured in unadjusted logistic regression models. Participants
in the lowest tertile of cystatin C (≤1.230 mg/L) served as
the reference group. Models were then adjusted for age,
race, education, and comorbidities. All analyses were com-
pleted using SAS version 9.1 (SAS Institute, Inc., Cary,
NC), and significance testing was two-sided, with a Type I
error rate of 5%.
RESULTS
The 821 participants had a mean age of 64.9, 50.6% were
male, and 48.6% were white. Participants with higher
cystatin C tended to be older and nonwhite and have less
education (P < .001 for all). The prevalence of diabetes
mellitus, hypertension, coronary heart disease, and stroke
increased (P < .05 for each comparison) and eGFR
decreased (P < .001) with increasing level of cystatin C
(Table 1). The Pearson correlation between eGFR and
cystatin-C was 0.82 (P < .001).
Participants with higher cystatin C levels had worse
cognitive performance on all cognitive tests than those
with intermediate and lower cystatin C levels in unad-
justed linear regression models (Table 2). After multivari-
able adjustment for age, race, education, and medical
Table 1. Baseline Characteristics of 821 Participants According to Cystatin C Tertile






n = 275 P-Valuea
Age, mean  SD 63.6  5.0 65.8  5.9 65.2  5.7 <.001
Age, n (%)
<65 168 (61.5) 123 (45.1) 129 (46.9) <.001
65–74 100 (36.6) 128 (46.9) 131 (47.6)
≥75 5 (1.8) 22 (8.1) 15 (5.5)
Male, n (%) 142 (52.0) 135 (49.5) 138 (50.2) .67
White, n (%) 151 (55.3) 136 (49.8) 112 (40.7) <.001
>High school education, n (%) 201 (73.6) 172 (63.0) 156 (56.7) <.001
Hispanic, n (%) 6 (2.2) 9 (3.3) 7 (2.6) .80
Diabetes mellitus, n (%) 93 (34.1) 155 (56.8) 176 (64.0) <.001
Hypertension (%) 223 (81.7) 258 (94.5) 267 (97.1) <.001
Coronary heart disease, n (%) 55 (20.2) 78 (28.6) 104 (37.8) <.001
Stroke, n (%) 25 (9.2) 41 (15.0) 41 (14.9) .046
Estimated glomerular filtration
rate, mL/min per 1.73 m2
54.8 (8.8) 41.8 (7.7) 27.5 (8.2) <.001
a For test of trend across tertiles of cystatin C.
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comorbidities including diabetes mellitus, hypertension,
coronary heart disease, and stroke, higher cystatin C levels
were associated with lower performance on the 3MS
(mean (SE): high tertile, 91.2 (0.6); middle tertile, 92.5
(0.6); low tertile, 93.2 (0.6)), Buschke Delayed Recall
(mean (SE): high tertile, 6.8 (0.3); middle tertile, 7.2 (0.3);
low tertile, 7.3 (0.3)), Trails A (mean (SE): high tertile,
70.5 (3.4); middle tertile, 61.9 (3.3); low tertile, 55.3
(3.4)), Trails B (mean (SE): high tertile, 176.5 (6.9); middle
tertile, 161.3 (6.7); low tertile, 152.7 (6.8)), and Boston
Naming (mean (SE): high tertile, 13.4 (0.2); middle tertile,
13.8 (0.2); low tertile, 13.9 (0.2)) (P < .05 for each com-
parison). The association with Verbal Fluency was no
longer significant (mean (SE): high tertile, 17.3 (0.5); mid-
dle tertile, 16.8 (0.5); low tertile, 17.3 (0.5), P = .90). To
determine whether the association between cystatin C and
cognition was independent of another measure of kidney
function, eGFR was also adjusted for in the full multivari-
able-adjusted model. In these models, Trails A and Bus-
chke Delayed Recall were still significantly associated with
cystatin C (P < .05 for each). There were no significant
interactions between age group and cystatin C level
(P > .05 for all).
Participants in the highest tertile of cystatin C had
greater risk of poor cognitive performance in unadjusted
models than those in the lowest tertile based on the 3MS
(OR = 2.73, 95% CI = 1.60–4.66), Buschke Delayed
Recall (OR = 1.99, 95% CI = 1.25–3.16), Trails A
(OR = 3.58, 95% CI = 2.03–6.31), Trails B (OR = 3.00,
95% CI = 1.85–4.85), and Boston Naming (OR = 2.54,
95% CI = 1.57–4.11). In models adjusted for age, race,
education, and comorbidities, these associations remained
statistically significant for Trails A (OR = 2.17, 95%
CI = 1.16–4.06) and B (OR = 1.89, 95% CI = 1.07–3.27),
and Boston Naming (OR = 1.85, 95% CI = 1.07–3.19)
(Figure 1).
CONCLUSION
In a group of older adults with CKD enrolled in a prospec-
tive cohort study, a significant association was found
between higher cystatin C levels and worse cognitive func-
tion for most cognitive domains, including global cogni-
tion, delayed memory, attention, executive function, and
naming. Participants in the highest tertile of cystatin C
were almost two times as likely to have significant poor
cognitive performance on attention, executive function,
and naming as those in the lowest tertile. Cystatin C was









Modified Mini-Mental State Examination
Unadjusted 94.9 (0.4) 93.0 (0.4) 91.1 (0.4) <.001
Adjustedb 93.2 (0.6) 92.5 (0.6) 91.2 (0.6) <.001
Buschke delayed recall
Unadjusted 7.9 (0.2) 7.4 (0.2) 6.9 (0.2) <.001
Adjusted 7.3 (0.3) 7.2 (0.3) 6.8 (0.3) .02
Trail-Making Test part A
Unadjusted 43.9 (2.2) 55.4 (2.2) 66.8 (2.2) <.001
Adjusted 55.3 (3.4) 61.9 (3.3) 70.5 (3.4) <.001
Trail-Making Test part B
Unadjusted 116.9 (4.7) 140.7 (4.7) 163.1 (4.8) <.001
Adjusted 152.7 (6.8) 161.3 (6.7) 176.5 (6.9) <.001
Boston naming
Unadjusted 14.2 (0.1) 13.9 (0.1) 13.4 (0.1) <.001
Adjusted 13.9 (0.2) 13.8 (0.2) 13.4 (0.2) .001
Verbal fluency
Unadjusted 18.7 (0.3) 17.5 (0.3) 17.6 (0.3) .01
Adjusted 17.3 (0.5) 16.8 (0.5) 17.3 (0.5) .97
a For test of linear trend.
b Adjusted for age, race, education, diabetes mellitus, hypertension, coronary heart disease, and stroke.
Figure 1. Adjusted odds ratios and 95% confidence intervals
for poor cognitive performance across cystatin C tertile (refer-
ence low). Models adjusted for age, race, education, diabetes
mellitus, hypertension, coronary heart disease, and stroke.
Trails = Trail-Making Test Part.
1626 YAFFE ET AL. SEPTEMBER 2014–VOL. 62, NO. 9 JAGS
associated with attention and delayed memory after adjust-
ing for eGFR. There was no difference in the relationship
between cystatin C level and cognitive function according
to age group.
Several studies have demonstrated that elderly adults
with impaired kidney function have a greater risk of cogni-
tive impairment and dementia based on measures of serum
creatinine.32–34 The current findings of an association
between cystatin C and cognitive function are consistent
with these previous studies and provide additional evi-
dence of a risk relationship between kidney function and
cognitive impairment. The reported associations also paral-
lel previous findings from the CRIC COG study that
described associations between eGFR according to the
Modification of Diet in Renal Disease and worse perfor-
mance on multiple cognitive domains, including global
cognition, executive function, naming, attention, and
delayed memory.24
The results of this study are also consistent with those
of longitudinal cohort studies of community-dwelling
older adults that found an association between high cysta-
tin C levels and incident cognitive decline as well as cogni-
tive and physical disability.4,5 High cystatin C levels have
also been associated with subclinical brain infarcts,35,36
and in a recent cohort study of older adults, markers of
kidney function, including high cystatin C levels, were
associated with poor global cognition and greater white
matter deficits in the anterior limb of the internal capsu-
lem,37 a region associated with impairment on executive
function and episodic memory,38 although the current
results are in contrast to those of other studies that sup-
port cystatin C’s relationship with cognitive function but
suggest that lower cystatin C levels correspond with
greater risk of poor cognitive outcomes, including incident
AD in a cohort of older men, conversion to AD in individ-
uals with mild cognitive impairment, and dementia in
individuals with Lewy body disease.6,7,39 These conflicting
reports may be due to differences in study populations,
study design, outcome definitions, or methods used to
measure cystatin C.
The cross-sectional association between cystatin C and
cognitive function in this study could be related to vascu-
lar pathology and shared pathways with cardiovascular
outcomes also linked to cystatin C, including hypertension,
obesity, and coronary heart disease.3,40–42 The current
results also suggest a significant relationship between cyst-
atin C and attention as well as delayed memory, even after
adjusting for eGFR, which suggests that cystatin C could
affect the pathological changes found in AD through path-
ways not associated with kidney function. Several lines of
evidence also support a role for cystatin C in neurodegen-
erative pathways involving amyloid plaque formation, as
demonstrated by its colocalization with b-amyloid in brain
tissue11 and a high correlation with beta-amyloid and tau
levels in cerebrospinal fluid.43 In animal models, cystatin C
knockout mice have lower levels of soluble beta-amyloid,
low plaque formation, and lower cognitive deficits,44 sug-
gesting that higher cystatin C levels may increase AD
pathology, although some in vitro and in vivo studies indi-
cate that cystatin C is neuroprotective and binds directly
to beta-amyloid to prevent plaque formation and preserve
cognition.1,45,46
A number of studies indicate that cystatin C is a reli-
able marker for risk stratification in elderly adults with
and without CKD, which may be attributable to its role as
a sensitive measure of kidney function or to its relation-
ships with non-GFR determinants such as inflamma-
tion.14–17,47,48 The current results suggest a possible
relationship between cystatin C and worse cognition inde-
pendent of eGFR levels. In earlier investigations of the
association between cystatin C and cognitive function,
studies that accounted for eGFR, by stratification or
adjustment, reported that cystatin C remained significantly
associated with cognitive impairment, although these
cohorts focused on healthy older adults.5,6 The current
findings suggest that, in those with CKD, cystatin C is
complementary to creatinine-based eGFR in its association
with cognitive function, but it may also provide additional
prognostic value. The observed association between cysta-
tin C and specific cognitive domains could be related to
non-GFR determinants of cystatin C.
The current study had a number of strengths, includ-
ing participant recruitment from the ongoing multicenter
CRIC Study, which comprises a large cohort of diverse
individuals. As a result, it was possible to evaluate cogni-
tive performance on a variety of cognitive tests. In addi-
tion, CRIC participants are well characterized, with
complete data on many participant characteristics, includ-
ing sociodemographic variables and cardiovascular
comorbidities, allowing for adjustment for several
potential covariates and confounders as well as level of
kidney function.
These results should be interpreted in light of the
study limitations. This was a cross-sectional analysis, so
causality cannot be inferred. In addition, data were not
available on structural brain imaging or pathological
results to determine the etiology of clinically significant
poor cognitive performance. Finally, these findings may
not be generalizable to younger populations because the
CRIC COG cohort was composed of older adults.
This study found that high cystatin C levels were asso-
ciated with greater likelihood of poor cognitive perfor-
mance in older adults with CKD, and for some domains,
this association was independent of eGFR levels. Although
the effect sizes were small, and the findings are prelimin-
ary, the findings suggest a need for further investigation to
determine the relationship between cystatin C levels and
cognitive outcomes in healthy individuals and those with
CKD, as well as for additional longitudinal studies to
determine the potential role for cystatin C as a biomarker
for cognitive decline.
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